Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2/3. fázis

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A legfontosabb adatok

Ki végzi
Ankara City Hospital Bilkent
Hol
Törökország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2/3. fázis
Résztvevők
90 fő, tervezett
Kezdés
2025. dec. 29.
Várható befejezés
2028. dec. 29.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Umbilical Cord-Derived Mesenchymal Stem Cells
  • Umblical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes
  • Placebo Intracavernosal Injection
A regiszteradat frissítve
2026. március 18.

Ki vehet részt

Életkor
25 év – 75 év
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Male patients aged 25 to 75 years
  • Diagnosis of erectile dysfunction for at least 6 months
  • Type 1 or Type 2 diabetes mellitus for at least 5 years
  • Inadequate response to medical treatment, including phosphodiesterase type-5 (PDE-5) inhibitors and/or intracavernosal prostaglandin E1 therapy
  • Candidates for penile prosthesis implantation due to treatment-resistant erectile dysfunction
  • Ability and willingness to provide written informed consent

Ki nem vehet részt

  • Previous penile prosthesis implantation, penile vascular surgery, or pelvic surgery
  • Use of immunosuppressive therapy
  • Active infection or skin lesion on the penis
  • Bleeding disorders or coagulation abnormalities
  • Unstable cardiovascular disease
  • History of malignancy
  • Autoimmune disease
  • Presence of systemic or local infection
  • Uncontrolled diabetes mellitus
  • Penile anatomical deformities
  • Untreated hypogonadism

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 25 és 75 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this prospective randomized controlled clinical study is to evaluate the effectiveness and safety of intracavernosal injections of umbilical cord-derived mesenchymal stem cells (MSCs) and umbilical cord-derived MSC-derived exosomes in men aged 25 to 75 years with diabetic erectile dysfunction (ED) who have not responded adequately to conventional medical treatments such as phosphodiesterase type-5 (PDE-5) inhibitors.

A teljes eredeti leírásKevesebb

Diabetes mellitus is a major risk factor for erectile dysfunction and is associated with endothelial dysfunction, impaired smooth muscle relaxation, neuropathy, and increased fibrosis within penile tissue. Although many patients respond to standard pharmacological treatments, diabetic patients often demonstrate reduced responsiveness to these therapies. Regenerative medicine approaches, including stem cell therapy and stem cell-derived exosomes, have emerged as potential therapeutic strategies due to their regenerative, angiogenic, neuroprotective, and anti-fibrotic effects.

The main questions this study aims to answer are:

* Whether intracavernosal administration of mesenchymal stem cells or MSC-derived exosomes improves erectile function, as measured by changes in the International Index of Erectile Function-5 (IIEF-5) and Erectile Hardness Score (EHS). * Whether penile hemodynamics improve following treatment, as assessed by penile Doppler ultrasonography parameters including peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI).

Participants will be randomly assigned to one of three groups:

* Intracavernosal placebo injection * Intracavernosal injection of umbilical cord-derived mesenchymal stem cells (5×10⁶ cells) * Intracavernosal injection of umbilical cord-derived mesenchymal stem cell-derived exosomes (75 μg) All interventions will be administered as a single intracavernosal injection under controlled clinical conditions.

Participants will undergo baseline evaluation including medical history, physical examination, erectile function assessment using the IIEF-5 questionnaire, and penile Doppler ultrasonography. Follow-up evaluations will be conducted at 1, 3, 6, and 12 months after treatment to assess changes in erectile function, penile vascular parameters, and treatment-related adverse events.

The study will also monitor potential side effects such as pain, bruising, hematoma, edema, or other complications related to the intracavernosal injection procedure.

Participants will be recruited from patients presenting to the urology outpatient clinic with diabetic erectile dysfunction. Eligible participants must have a diagnosis of erectile dysfunction for at least six months, a history of diabetes mellitus for at least five years, and insufficient response to standard medical therapy. Patients with penile anatomical deformities, active infections, malignancy, unstable cardiovascular disease, autoimmune disease, or other contraindications to intracavernosal treatment will be excluded.

A vizsgálat 3 csoportja

  • Mesenchymal Stem Cell Treatment GroupA vizsgált kezelés

    Participants in this group will receive a single intracavernosal injection of umbilical cord-derived mesenchymal stem cells (5×10⁶ cells). The stem cells are produced under Good Manufacturing Practice (GMP) conditions and administered directly into the corpus cavernosum. The treatment aims to improve erectile function by promoting angiogenesis, tissue regeneration, and improved penile vascular function. Participants will be followed for safety and efficacy outcomes during scheduled follow-up visits.

    Kezelés: Umbilical Cord-Derived Mesenchymal Stem Cells

  • Exosome Treatment GroupA vizsgált kezelés

    Participants in this group will receive a single intracavernosal injection of umbilical cord-derived mesenchymal stem cell-derived exosomes (75 μg). Exosomes are extracellular vesicles that contain growth factors and signaling molecules that may promote tissue repair and vascular regeneration. This cell-free regenerative therapy aims to improve erectile function in patients with diabetic erectile dysfunction.

    Kezelés: Umblical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes

  • Placebo Control GroupPlacebo, összehasonlításként

    Participants in this group will receive a single intracavernosal injection of sterile normal saline (0.9% sodium chloride solution) as placebo. The placebo injection will be administered using the same procedure as the treatment groups in order to maintain study blinding. Participants will undergo the same follow-up assessments as the other study groups.

    Kezelés: Placebo Intracavernosal Injection

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Safety and Efficiacy of Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction: A Randomized Placebo-Controlled Clinical Trial
Kérdések a feltételekről
Forrás: NCT07480161: ki vehet részt
A regiszteradat frissítve
2026. március 18.